NCT02195973 2026-02-09
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
University of Alabama at Birmingham
Phase 1 Completed
Clinical Trials
12 trialsNCT03434262 2024-05-31
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02027376 2023-04-03
EDALINE
Spanish Breast Cancer Research Group
Phase 1 Completed
NCT01208831 2020-12-19
An East Asian Study of LDE225
Novartis
Phase 1 Completed
NCT01769768 2020-12-19
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients
Novartis
Phase 1 Completed
NCT01456676 2020-12-09
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
Novartis
Phase 1 Completed
NCT01954355 2019-12-06
LDE225 and Paclitaxel in Solid Tumors
Swiss Cancer Institute
Phase 1 Completed
NCT02129101 2019-10-30
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Mayo Clinic
Phase 1 Completed
NCT02182622 2019-06-19
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Hackensack Meridian Health
Phase 1 Withdrawn
NCT02111187 2019-03-07
LDE225
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02151864 2019-03-05
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
University of California, San Diego
Phase 1 Completed
NCT01579929 2017-08-17
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed